The Hindu Business Line : Sun Pharma gets US nod for Trileptal

Chennai, Oct 10 Sun Pharmaceutical Industries Ltd has announced that the USFDA has granted final approval for the company’s abbreviated new drug application to market its generic version of Novartis Trileptal oxcarbazepine tablets, used in the treatment of epilepsy. These generic oxcarbazepine tablets are AB-rated equivalent of Novartis Trileptal tablets.. Trileptal has annual sales of $640 million in the US.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
L&T bags $60-m Saudi order

No VRS to employees facing criminal charge, rules Madurai Bench

Cambridge Tech to hike capital

Shasun Chem may split research, manufacturing operations

Lupin takes majority stake in Japanese generic co

Nucleus Software to sell its 25% stake in GMAC Finanical

Buyout: No short-term benefits for Lupin

Donear on expansion spree; setting up new plant in Surat

Madurai getting mega dairy unit

TCC in expansion mode

IOC in talks with RIL for joint exploration

S Kumars foraying into West Asia

Sun Pharma gets US nod for Trileptal

‘Marketing tie-ups between hotel chains enhance brand awareness’

Mahindra joins the retail bandwagon

Bharat Gold Mines to be revived

PowerGrid plans Rs 16,500-cr investments

Godrej SED sets eyes on export market